|Articles|September 21, 2015

HHS to Fund Regeneron's Efforts for Antibody Against Ebola

Author(s)AJMC Staff

The collaboration will make available 3 fully-humanized monoclonal antibodies to fight the devastating virus.

The US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has entered into an agreement with Tarrytown-based Regeneron Pharmaceuticals, Inc to develop a treatment regimen that includes 3 monoclonal antibodies against the Ebola virus.

The company has developed the 3 fully-humanized monclonal antibodies using their propreitory VelociGene and VelocImmune technologies, and will receive $38 million over a 2-year period for further development and manufacturing of the monoclonal antibodies.

Read the associated press release by HHS here.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo